Lakefront Biotherapeutics (LKFT) Receivables - Other (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Receivables - Other for 13 consecutive years, with $37.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other rose 11.14% year-over-year to $37.8 million; the TTM figure through Mar 2026 stood at $37.8 million (up 11.14% YoY), while the FY2025 annual figure was $36.3 million, up 234.6% from the prior year.
• Receivables - Other advanced to $37.8 million in Q1 2026 per LKFT's latest filing, from $36.3 million in the prior quarter.
• Across five years, Receivables - Other topped out at $45.9 million in Q3 2024 and bottomed at $5.6 million in Q4 2023.
• Historically, Receivables - Other has averaged $28.4 million across 5 years, with a median of $34.0 million in 2025.
• Annual changes were most pronounced in 2022 — Receivables - Other plunged 44.25% — and 2025, when it soared 234.6%.
• Lakefront Biotherapeutics' Receivables - Other stood at $8.0 million in 2022, then tumbled by 30.41% to $5.6 million in 2023, then jumped by 94.13% to $10.9 million in 2024, then jumped by 234.6% to $36.3 million in 2025, then increased by 4.08% to $37.8 million in 2026.
• Business Quant data shows LKFT's Receivables - Other at $37.8 million in Q1 2026, $36.3 million in Q4 2025, and $37.8 million in Q3 2025.